Neuronetics Inc (STIM)
Official siteHEALTHCARE • MEDICAL DEVICES • NASDAQ
Market Cap: $120.60M
Last updated: Nov 17, 2026 at 4:41 PM ET
Neuronetics Inc (STIM) Statistics
Neuronetics (STIM) has a market cap of $120.60M and an enterprise value of $160.49M. Its share count is up 14.40% from a year earlier. Revenue grew 23.01% over the last 12 months from the 12 months before.
Total Valuation
Enterprise value is 33.08% above the market cap, as debt exceeds cash.
| Market Cap | $120.60M |
|---|---|
| Enterprise Value | $160.49M |
| Latest price (Nov 17, 2026) | $1.28 |
Key Dates
The next earnings report is expected on Mar 15, 2027, covering the quarter ending Dec 31, 2026.
| Next Earnings Date | Mar 15, 2027 (expected) |
|---|---|
| Last Earnings Date | Nov 4, 2026 |
| Fiscal Year End | December |
Valuation Ratios
Sales and book value multiples are 0.6x and 5.3x. Its year-end P/S ranged from 0.3x to 4.3x from 2018 to 2025.
| P/S Ratio | 0.6x |
|---|---|
| Forward P/S | 0.7x |
| P/B Ratio | 5.3x |
Price Statistics
The stock is down 35.68% over 52 weeks and trades 43.86% below its 50-day average.
| Beta (1Y) | 2.10 |
|---|---|
| 52-Week Change | -35.68% |
| 1-Month Change | -32.98% |
| 3-Month Change | -59.24% |
| 6-Month Change | +8.47% |
| 5-Year Change | -56.73% |
| Total Return (1Y) | -35.68% |
| Total Return (3Y CAGR) | -1.76% |
| Total Return (5Y CAGR) | -20.86% |
| Return vs SPY (1Y) | -25.94% |
| Max Drawdown (1Y) | -62.12% |
| Max Drawdown (3Y) | -87.33% |
| Sharpe Ratio (1Y) | -0.14 |
| Correlation with SPY (1Y) | 0.25 |
| 50-Day Average | $2.28 |
| 200-Day Average | $1.86 |
| 52-Week Range | $0.80 to $3.44 |
| RSI (14 Days) | 30.5 |
| Average Volume (20 Days) | 3.18M |
The 5-year change compares month-end closes, adjusted for splits, through Oct 2026.
Financial Position
Current assets cover 2.01x current liabilities, and total debt is 3.31x shareholder equity.
| Current Ratio | 2.01x |
|---|---|
| Quick Ratio | 1.82x |
| Debt / Equity | 3.31x |
| Interest Coverage | -1.45x |
Returns and Efficiency
Return on invested capital is -13.33% over the last 12 months, against a 5-year average of -24.84%.
| Return on Equity (ROE) | -122.97% |
|---|---|
| Return on Assets (ROA) | -17.43% |
| Return on Invested Capital (ROIC) | -13.33% |
| Return on Capital Employed (ROCE) | -12.95% |
| ROA (5Y Average) | -27.72% |
| ROIC (5Y Average) | -24.84% |
| Asset Turnover | 1.15x |
| Inventory Turnover | 15.09x |
| Receivables Turnover | 10.51x |
| Cash Conversion Cycle | 7 days |
Scores
STIM has an Altman Z-Score of -3.38, in the distress zone below 1.81, and a Piotroski F-Score of 4 of 9, in the average band of 3 to 7.
Altman Z-ScoreDistress below 1.81Safe above 2.99
Piotroski F-ScoreWeak at 2 or lessStrong at 8 or more
| Altman Z-Score | -3.38 |
|---|---|
| Altman Z Zone | Distress |
| Piotroski F-Score | 4 of 9 |
| Piotroski Strength | Average |
Income Statement
Revenue was $159.76M over the last 12 months.
| Revenue | $159.76M |
|---|---|
| Revenue Growth (YoY) | +23.01% |
| Gross Profit | $80.97M |
| Operating Income | -$15.00M |
| Pretax Income | -$23.01M |
| Net Income | -$23.01M |
| EBITDA | -$9.70M |
| EBIT | -$13.61M |
| Reported EPS (TTM) | -$0.32 |
Trailing 12 months through Sep 30, 2026.
Balance Sheet
Shareholder equity funds 14.18% of the $131.96M in total assets.
| Cash and Equivalents | $22.11M |
|---|---|
| Total Debt | $62.00M |
| Net Debt | $39.90M |
| Net Debt Per Share | $0.52 |
| Working Capital | $27.03M |
| Shareholder Equity | $18.71M |
| Book Value Per Share | $0.24 |
| Tangible Book Value | -$21.97M |
| Total Assets | $131.96M |
| Total Liabilities | $109.56M |
Balance sheet as of Sep 30, 2026.
Cash Flow
After $1.30M of capital spending, operating cash flow left -$9.58M of free cash flow.
| Operating Cash Flow | -$8.28M |
|---|---|
| Capital Expenditures | $1.30M |
| Free Cash Flow | -$9.58M |
| FCF Per Share | -$0.13 |
| Depreciation and Amortization | $3.92M |
| Share Repurchases | $545.00K |
Trailing 12 months through Sep 30, 2026.
Margins
The operating margin is -9.39%, against a 5-year average of -42.75%.
| Gross Margin | 50.68% |
|---|---|
| Operating Margin | -9.39% |
| Pretax Margin | -14.40% |
| Net Margin | -14.40% |
| EBITDA Margin | -6.07% |
| EBIT Margin | -8.52% |
| FCF Margin | -6.00% |
| Gross Margin (5Y Average) | 69.69% |
| Operating Margin (5Y Average) | -42.75% |
| Net Margin (5Y Average) | -48.06% |
Growth
Revenue grew 31.76% a year over 3 years.
| Revenue Growth (3Y CAGR) | +31.76% |
|---|---|
| Revenue Growth (5Y CAGR) | +24.81% |
| Book Value Per Share Growth (2Y CAGR) | -47.41% |
Dividends and Yields
STIM does not pay a dividend. Its free cash flow yield is -9.72%.
| FCF Yield | -9.72% |
|---|---|
| Buyback Yield | -8.15% |
Peer Position
Against 12 similar companies, STIM has the 11th highest P/S.
P/S RatioPeer median 2.0x
ROICPeer median -41.53%
Revenue Growth (Trailing 4 Quarters, YoY)Peer median +13.76%
| P/S Ratio | 0.6x vs 2.0x median |
|---|---|
| ROIC | -13.33% vs -41.53% median |
| Revenue Growth (Trailing 4 Quarters, YoY) | +23.01% vs +13.76% median |
Analyst Forecast
Consensus estimates put revenue growth at 8.92% a year over the next 2 fiscal years.
| Revenue Growth Forecast (2Y CAGR) | +8.92% |
|---|
Price Target
Analyst price targets are part of paid GNG plans. See plans
GNG Valuation
| GNG view | Fairly valued |
|---|
GNG fair value is part of GNG Pro. See plans
Frequently Asked Questions About STIM
What is STIM's market cap?
Neuronetics has a market cap of $120.60M. Its enterprise value, which adds debt and subtracts cash, is $160.49M.
How many shares of STIM are outstanding?
Neuronetics has 77.00M shares outstanding. The count is up 14.40% from a year earlier.
Does STIM pay a dividend?
No. Neuronetics does not pay a dividend.
How much debt does STIM have?
Neuronetics has $62.00M of total debt and $22.11M of cash and equivalents, a net debt position of $39.90M.
STIM pages: Overview, Charting, Earnings, Forecast, Financials, Statistics, Valuation, Competitors, Government Contracts